Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.


TSX:APLI - Post by User

Post by calgarydaveon Oct 04, 2020 6:31am
433 Views
Post# 31664055

Stock Price up 100% in a month and not a tweet on this board

Stock Price up 100% in a month and not a tweet on this boardNo news since they moved to TSX but the price has moved dramatically and is moving close to all time high of $1.80.
My call is that they are getting close to a licencing agreement with Fujifilm for Favipiravir.
They are in trials in Ontario and USA on a Sponsorship agreement but they need exclusive licencing rights to monetize this arrangement.
The company appears to have a long relationship with Fujifilm. In November 2019 they assigned worldwide rights to the company to develope and commercialise another antifungal drug ATI-2307.
Hopefully we can get the rights to Canada and USA as I believe no one else is in trials on this drug in these countries. Trials are underway worldwide with other companies.
My feeling is that this tablet form theraputic for Covid 19 is the best candidate for early stages cure within about 4 days from treatment compared to other candidates. I have been closely monitoring its progress since early this year and sent reports to the provincial government in March on the drug. My feeling is it beats everything else hands down.
If I am right and we get exclusive rights to it in N America this stock will explode out of our atmosphere.




<< Previous
Bullboard Posts
Next >>